A Randomized Phase 3 Study to Evaluate the Efficacy and Safety of NXC-201 Compared With Daratumumab With Cyclophosphamide, Bortezomib and Dexamethasone (CyBorD) in Newly Diagnosed Systemic AL Amyloidosis
Clinical trial NCT07709715 · NOT_YET_RECRUITING
Trial details
- NCT number
- NCT07709715
- Sponsor
- Nexcella Inc.
- Status
- NOT_YET_RECRUITING
- Phase
- Phase 3
- Study type
- INTERVENTIONAL
- Start date
- 2027-01-01
- Primary completion
- 2028-12-01
- Enrollment
- 260
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.